Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjogren's syndrome in mice by promoting TEC kinase degradation.

ABSTRACT: Primary Sjögren's syndrome (pSS) is a chronic inflammatory autoimmune disease with an unclear pathogenesis, and there is currently no approved drug for the treatment of this disease. Iguratimod, as a novel clinical anti-rheumatic drug in China and Japan, has shown remarkable efficacy in improving the symptoms of patients with pSS in clinical studies. In this study we investigated the mechanisms underlying the therapeutic effect of iguratimod in the treatment of pSS. Experimental Sjögren's syndrome (ESS) model was established in female mice by immunizing with salivary gland protein. After immunization, ESS mice were orally treated with iguratimod (10, 30, 100 mg·kg^-1·d^-1) or hydroxychloroquine (50 mg·kg^-1·d^-1) for 70 days. We showed that iguratimo

SUBMITTER: Yang YQ 

PROVIDER: S-EPMC11336088 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature